Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood in trisomy 21.
paper
Cited
Public
Unavailable
- Authors
- Grinspon, R P; Bedecarrás, P; Ballerini, M G; Iñiguez, G; Rocha, A; Mantovani Rodrigues Resende, E A; Brito, V N; Milani, C; Figueroa Gacitúa, V; Chiesa, A; Keselman, A; Gottlieb, S; Borges, M F; Ropelato, M G; Picard, J-Y; Codner, E; Rey, R A; LAREP Group
- Year
- 2011
- Journal
- International journal of andrology
- PMID
- 21831236
- DOI
- 10.1111/j.1365-2605.2011.01210.x
Male patients with an extra sex chromosome or autosome are expected to present primary hypogonadism at puberty owing to meiotic germ-cell failure. Scarce information is available on trisomy 21, a frequent autosomal aneuploidy. Our objective was to assess whether trisomy 21 presents with pubertal-onset, germ-cell specific, primary hypogonadism in males, or whether the hypogonadism is established earlier and affects other testicular cell populations. We assessed the functional status of the pituitary-testicular axis, especially Sertoli cell function, in 117 boys with trisomy 21 (ages: 2months-20year). To compare with an adequate control population, we established reference levels for serum anti-Müllerian hormone (AMH) in 421 normal males, from birth to adulthood, using a recently developed ultrasensitive assay. In trisomy 21, AMH was lower than normal, indicating Sertoli cell dysfunction, from early infancy, independently of the existence of cryptorchidism. The overall prevalence rate of AMH below the 3rd percentile was 64.3% in infants with trisomy 21. Follicle-stimulating hormone was elevated in patients <6months and after pubertal onset. Testosterone was within the normal range, but luteinizing hormone was elevated in most patients <6months and after pubertal onset, indicating a mild Leydig cell dysfunction. We conclude that in trisomy 21, primary hypogonadism involves a combined dysfunction of Sertoli and Leydig cells, which can be observed independently of cryptorchidism soon after birth, thus prompting the search for new hypotheses to explain the pathophysiology of gonadal dysfunction in autosomal trisomy.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. | 2014 | 25231870 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A Novel POR G88S Mutation Causes Severe PORD and Establishes a Critical Pharmacogenomic Risk Profile. | Rojas Velazquez MN et al. | — | 2026 | → |
| 46,XX Testicular/Ovotesticular Disorders of Sexual Development: A Single-Center Retrospective Experience. | Costanzo M et al. | — | 2025 | → |
| A focused evaluation of genetic and epigenetic contributions to common infertility conditions. | Gunes S et al. | — | 2025 | → |
| Clinical approach to the male with delayed puberty. | Rey RA et al. | — | 2025 | → |
| Effect of pubertal induction with combined gonadotropin therapy on testes development and spermatogenesis in males with gonadotropin deficiency: a cohort study. | Castro S et al. | — | 2025 | → |
| FSH and Sertoli Cell Biomarkers Accurately Distinguish Hypogonadotropic Hypogonadism From Self-limited Delayed Puberty. | Castro S et al. | — | 2025 | → |
| Male hypogonadism in transition age: fertility outcomes and practical management. | Spaziani M et al. | — | 2025 | → |
| Psychosocial Stress Trajectories Are Associated With Puberty Timing: Findings From a 7-Year Cohort in Chongqing, China. | Liu S et al. | — | 2025 | → |
| Anti-Müllerian hormone, testicular descent and cryptorchidism. | Rey RA et al. | — | 2024 | → |
| Assessment of testicular function in boys and adolescents. | Lopez Dacal J et al. | — | 2024 | → |
| Central Precocious Puberty in a Male Child With Down Syndrome: A Case Report. | Al Noaim K | — | 2024 | → |
| Endocrine, auxological and metabolic profile in children and adolescents with Down syndrome: from infancy to the first steps into adult life. | Molinari S et al. | — | 2024 | → |
| Weight Loss Improved Hypothalamic GH Deficiency but not Hypogonadotropic Hypogonadism in a Man With Down Syndrome. | Nakagawa Y et al. | — | 2024 | → |
| A novel c.64G > T (p.G22C) NR5A1 variant in a Chinese adolescent with 46,XY disorders of sex development: a case report. | Zhang D et al. | — | 2023 | → |
| A Surgical and Clinical Approach to Persistent Müllerian Duct Syndrome: Laparoscopic, Histological, and Molecular Findings. | Mattone MC et al. | — | 2023 | → |
| Steroid receptors in the testis: implications in the physiology of prenatal and postnatal development and translation to clinical application. | Rey RA | — | 2023 | → |
| Testicular dysfunction at diagnosis in children and teenagers with haematopoietic malignancies improves after initial chemotherapy. | Lopez Dacal J et al. | — | 2023 | → |
| Up-to-Date Clinical and Biochemical Workup of the Child and the Adolescent with a Suspected Disorder of Sex Development. | Grinspon RP et al. | — | 2023 | → |
| AMH and AMHR2 Involvement in Congenital Disorders of Sex Development. | Brunello FG et al. | — | 2022 | → |
| AMH Regulation by Steroids in the Mammalian Testis: Underlying Mechanisms and Clinical Implications. | Edelsztein NY et al. | — | 2022 | → |
| Delayed Puberty Due to a WDR11 Truncation at Its N-Terminal Domain Leading to a Mild Form of Ciliopathy Presenting With Dissociated Central Hypogonadism: Case Report. | Castro S et al. | — | 2022 | → |
| Genetics of congenital central hypogonadism. | Grinspon RP | — | 2022 | → |
| GnRH replacement rescues cognition in Down syndrome. | Manfredi-Lozano M et al. | — | 2022 | → |
| Is there a secular trend regarding puberty in children with down syndrome? | Erdoğan F et al. | — | 2022 | → |
| Recent advancement in the treatment of boys and adolescents with hypogonadism. | Rey RA | — | 2022 | → |
| Review of the Function of the Hypothalamic-Pituitary-Gonadal Axis in Children and Adolescents with Cancer. | Lopez Dacal J et al. | — | 2022 | → |
| Testosterone therapy in children and adolescents: to whom, how, when? | Suarez A MC et al. | — | 2022 | → |
| Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells. | Chauvin M et al. | — | 2021 | → |
| Diagnosis of Male Central Hypogonadism During Childhood. | Grinspon RP et al. | — | 2021 | → |
| The Role of Androgen Signaling in Male Sexual Development at Puberty. | Rey RA | — | 2021 | → |
| What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of 'Internal Medicine for Rare Genetic Syndromes'. | Rosenberg AGW et al. | — | 2021 | → |
| Androgen Treatment in Adolescent Males With Hypogonadism. | Rey RA et al. | — | 2020 | → |
| Biomarkers of male hypogonadism in childhood and adolescence. | Rey RA | — | 2020 | → |
| Development and Validation of a Prediction Rule for Growth Hormone Deficiency Without Need for Pharmacological Stimulation Tests in Children With Risk Factors. | Clément F et al. | — | 2020 | → |
| Male Hypogonadism and Disorders of Sex Development. | Grinspon RP et al. | — | 2020 | → |
| What Does AMH Tell Us in Pediatric Disorders of Sex Development? | Josso N et al. | — | 2020 | → |
| Comparing the role of anti-Müllerian hormone as a marker of FSH action in male and female fertility. | Urrutia M et al. | — | 2019 | → |
| Down syndrome and infertility: what support should we provide? | Parizot E et al. | — | 2019 | → |
| Has GnRH a direct role in AMH regulation? | van Helden J et al. | — | 2019 | → |
| Hypogonadism in Pediatric Health: Adult Medicine Concepts Fail. | Grinspon RP et al. | — | 2019 | → |
| Neonatal Hypopituitarism: Approaches to Diagnosis and Treatment | Kurtoğlu S et al. | — | 2019 | → |
| Paediatric and adult-onset male hypogonadism. | Salonia A et al. | — | 2019 | → |
| Regulation of anti-Müllerian hormone (AMH) in males and the associations of serum AMH with the disorders of male fertility. | Xu HY et al. | — | 2019 | → |
| Safety of standardised treatments for haematologic malignancies as regards to testicular endocrine function in children and teenagers. | Grinspon RP et al. | — | 2019 | → |
| Accelerated Pubertal Tempo in a 46,XY Aromatase-Deficient Patient. | Costanzo M et al. | — | 2018 | → |
| Anti-Müllerian Hormone and Testicular Function in Prepubertal Boys With Cryptorchidism. | Grinspon RP et al. | — | 2018 | → |
| Cancer treatment in childhood and testicular function: the importance of the somatic environment. | Stukenborg JB et al. | — | 2018 | → |
| Endocrine manifestations of Down syndrome. | Whooten R et al. | — | 2018 | → |
| Male Central Hypogonadism in Paediatrics - the Relevance of Follicle-stimulating Hormone and Sertoli Cell Markers. | Grinspon RP et al. | — | 2018 | → |
| Noonan syndrome males display Sertoli cell-specific primary testicular insufficiency. | Moniez S et al. | — | 2018 | → |
| Spontaneous virilization around puberty in NR5A1-related 46,XY sex reversal: additional case and a literature review. | Adachi M et al. | — | 2018 | → |
| Anti-Müllerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis. | Edelsztein NY et al. | — | 2016 | → |
| Compensatory function of the remaining testis is dissociated in boys and adolescents with monorchidism. | Grinspon RP et al. | — | 2016 | → |
| Perspectives in Pediatric Pathology, Chapter 17. Other Hypergonadotropic Hypogonadisms. | Nistal M et al. | — | 2016 | → |
| Anti-Müllerian hormone is a gonadal cytokine with two circulating forms and cryptic actions. | McLennan IS et al. | — | 2015 | → |
| Validation of an immunoassay for anti-Müllerian hormone measurements and reference intervals in healthy Brazilian subjects. | Woloszynek RR et al. | — | 2015 | → |
| Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. | Perry JR et al. | — | 2014 | → |
| Spreading the clinical window for diagnosing fetal-onset hypogonadism in boys. | Grinspon RP et al. | — | 2014 | → |
| Testicular function during adolescence in boys with type 1 diabetes mellitus (T1D): absence of hypogonadism and differences in endocrine profile at the beginning and end of puberty. | Rocha A et al. | — | 2014 | → |
| A novel mutation of anti-Mullerian hormone gene in Persistent Mullerian Duct Syndrome presented with bilateral cryptorchidism: a case report. | Wongprasert H et al. | — | 2013 | → |
| Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. | Josso N et al. | — | 2013 | → |
| Male Central Precocious Puberty: Serum Profile of Anti-Müllerian Hormone and Inhibin B before, during, and after Treatment with GnRH Analogue. | Grinspon RP et al. | — | 2013 | → |
| Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. | Rey RA et al. | — | 2013 | → |
| Serum AMH in Physiology and Pathology of Male Gonads. | Matuszczak E et al. | — | 2013 | → |
| The prepubertal testis: biomarkers and functions. | Valeri C et al. | — | 2013 | → |
| Decline in serum antimüllerian hormone due to androgen action in early puberty in males. | Grinspon R et al. | — | 2012 | → |
| New perspectives in the diagnosis of pediatric male hypogonadism: the importance of AMH as a Sertoli cell marker. | Grinspon RP et al. | — | 2011 | → |